N-(2-叠氮基乙基)氨基甲酸叔丁酯 | 117861-38-8

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(2-叠氮基乙基)氨基甲酸叔丁酯
• 中文别名: N-Boc-2-叠氮基乙胺；N-BOC-2-叠氮基乙胺
• 英文名称: tert-butyl 2-azidoethylcarbamate
• 英文别名: N-Boc-2-azidoethylamine；(2-azido-ethyl)-carbamic acid tert-butyl ester；tert-butyl N-(2-azidoethyl)carbamate
• CAS: 117861-38-8
• 化学式: C₇H₁₄N₄O₂
• mdl: MFCD18207539
• 分子量: 186.214
• InChiKey: KHZVCESAQNHHKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  52.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2929909090
• 储存条件：
  2-8°C

制备方法与用途

N-BOC-2-叠氮基乙胺是一种适用于有机合成及其他化学过程的研究级化学品，具有广泛的应用价值。

反应信息

• 作为反应物：
  描述：

  N-(2-叠氮基乙基)氨基甲酸叔丁酯 在 镍 一水合肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以50 mg的产率得到N-叔丁氧羰基-1,2-乙二胺
  参考文献：
  名称：

  Structure-activity relationships of novel vasopressin antagonists containing C-terminal diaminoalkanes and (aminoalkyl)guanidines

  摘要：

  We report the synthesis and biological activity of a series of analogues of the vasopressin antagonists [Pmp1,D-Tyr(Et)2,Val4]arginine-vasopressin (1) and [Pmp1,D-Tyr(Et)2,Val4,desGly9]arginine-vasopressin (2), where part or all of the tripeptide tail has been replaced by a simple alkyldiamine [NH(CH2)nNH2] or (aminoalkyl)guanidine [NH(CH2)nNHC(= NH)NH2] in order to examine the effects that variation of the length and orientation of the tripeptide tail have on renal vasopressin (V2) receptor antagonist activity. The results show that the entire tripeptide tail (Pro-Arg-Gly-NH2) can be replaced by an alkyldiamine or an (aminoalkyl)guanidine, compounds 15 and 16, respectively, indicating that there is no orientational requirement for the basic functional group coming off the cyclic hexapeptide ring. Also, there seems to be an "optimal" distance between the basic functional group and the hexapeptide ring since receptor affinity of the antagonists begins to fall off when the basic functional group is too close (compound 13) or extends too far (compounds 8-10) from the hexapeptide ring. These results suggest all that is necessary for retention of antagonist affinity and potency is a basic functional group, amine or guanidine, extended an optimal distance from the hexapeptide ring.

  DOI：

  10.1021/jm00122a017
• 作为产物：
  描述：

  N-叔丁氧羰基-1,2-乙二胺 在 盐酸 、 sodium nitrite 、 sodium azide 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 N-(2-叠氮基乙基)氨基甲酸叔丁酯
  参考文献：
  名称：

  金属结合药效团点击衍生的新型广谱金属-β-内酰胺酶抑制剂的发现

  摘要：

  金属-β-内酰胺酶（MBL）的出现赋予了对几乎所有β-内酰胺抗生素（包括碳青霉烯类）的耐药性。目前，缺乏临床上有用的 MBL 抑制剂，因此发现能够有效靶向多种临床相关 MBL 的新抑制剂化学型至关重要。在此，我们报告了一种利用金属结合药效团 (MBP) 点击方法来识别新的广谱 MBL 抑制剂的策略。我们的初步研究确定了几种 MBP，包括邻苯二甲酸、苯基硼酸和苄基磷酸，它们使用叠氮-炔点击反应进行结构转变。随后的结构-活性关系分析导致了几种有效的广谱 MBL 抑制剂的鉴定，包括针对多种 MBL 的 IC 值范围为 0.00012 μM 至 0.64 μM。共晶研究证明了 MBP 在与 MBL 活性位点锚定药效团特征结合方面的重要性，并揭示了与 IMP-1 不寻常的两分子结合模式，强调了灵活的活性位点环在识别结构多样的底物/抑制剂中的关键作用。我们的工作为 MBL 抑制提供了新的化学型，并为针对

  DOI：

  10.1016/j.ejmech.2023.115473

文献信息

• Synthesis and Characterization of Enzymatically Biodegradable PEG and Peptide-Based Hydrogels Prepared by Click Chemistry
  作者：Maarten van Dijk、Cornelus F. van Nostrum、Wim E. Hennink、Dirk T. S. Rijkers、Rob M. J. Liskamp

  DOI：10.1021/bm1002637

  日期：2010.6.14

  Herein we describe the synthesis and rheological characterization of a series of enzymatically sensitive PEG and peptide-based hydrogels by the Cu(I)-catalyzed 1,3-dipolar cycloaddition reaction. The hydrogels were synthesized by a combination of alkyne-functionalized star-shaped PEG molecules (two 4-armed PEGs with Mw 10 and 20 kDa, respectively, and one 8-armed PEG of 20 kDa) and the protease-sensitive

  在这里，我们描述了通过Cu（I）催化的1,3-偶极环加成反应，合成了一系列酶敏性PEG和基于肽的水凝胶，并对其进行了流变学表征。水凝胶是由炔官能化的星形PEG分子的组合合成的（具有两个4武装的PEG中号瓦特分别为10和20kDa，和一个8武装PEG 20kDa的的）和蛋白酶敏感双叠氮肽，N α - （叠氮基） - d -丙氨酰苯丙氨酰lysyl-（2-叠氮基乙基） -酰胺（6中的CuSO的存在下）4和抗坏血酸钠水溶液。溶胀率和储能模量（G可以通过几个参数，例如水凝胶的初始固体含量，PEG衍生物的分子量和PEG分子的结构（4臂对8臂的PEG衍生物）来定制水凝胶的′′）。肽序列d -Ala-Phe-Lys对蛋白酶纤溶酶和胰蛋白酶敏感，使水凝胶可生物降解。
• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors
  作者：Laurent Le Corre、Anne-Lise Girard、Johannes Aubertin、François Radvanyi、Catherine Benoist-Lasselin、Aurélie Jonquoy、Emilie Mugniery、Laurence Legeai-Mallet、Patricia Busca、Yves Le Merrer

  DOI：10.1039/b923882d

  日期：——

  A library of pyrido[2,3-d]pyrimidines was designed as inhibitors of FGFR3 tyrosine kinase allowing possible interactions with an unexploited region of the ATP binding-site. This library was built-up with an efficient step of click-chemistry giving easy access to triazole-based compounds bearing a large panel of substituents. Among the 27 analogues synthesized, more than half exhibited 55–89% inhibition of in vitro FGFR3 kinase activity at 2 μM and one (19g) was able to inhibit auto-phosphorylation of mutant FGFR3-K650M in transfected HEK cells.

  设计了一系列吡啶并[2,3-d]嘧啶类化合物作为FGFR3酪氨酸激酶的抑制剂，这些化合物可能与ATP结合位点的一个未开发区域发生相互作用。该化合物库通过高效的点击化学步骤构建，便于合成含有多种取代基的三唑类化合物。在合成的27个类似物中，超过一半的化合物在2微摩尔浓度下对体外FGFR3激酶活性表现出55-89%的抑制作用，其中一个化合物（19g）能够抑制转染HEK细胞中突变型FGFR3-K650M的自磷酸化。
• [EN] FLUORESCENT NEAR INFRA-RED (NIR) DYES<br/>[FR] COLORANTS FLUORESCENTS DANS LE PROCHE INFRAROUGE (NIR)
  申请人：HAE THERAPEUTICS

  公开号：WO2011048217A1

  公开（公告）日：2011-04-28

  A compound of formula (I) is described in which each A, which may be the same or different, is a halide selected from fluoride, chloride, bromide and iodide, or is O-Y, wherein Y is a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. R1, R2, R3, R6, R7, and R8 are each independently H, OH, NO2 or O-L-X, wherein L is a spacer group, and X is a conjugation group or a water- solubilizing group. At least one of R1, R2, R3 is OH or O-L-X and at least one of R6, R7, and R8 is OH or O-L-X. R4 and R5, which may be the same or different, are each independently H; or are a substituted or unsubstituted, saturated or unsaturated, cyclic moiety; a substituted or unsubstituted, saturated or unsaturated heterocyclic moiety; or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. Also described are dye conjugates comprising a compound of the invention.

  化合物的结构式（I）中描述了每个A，它可以相同也可以不同，是从氟化物、氯化物、溴化物和碘化物中选择的卤素，或者是O-Y，其中Y是取代或未取代的、饱和或不饱和的、直链或支链烷基基团。R1、R2、R3、R6、R7和R8各自独立地是H、OH、NO2或O-L-X，其中L是一个间隔基团，X是一个共轭基团或水溶性基团。R1、R2、R3中至少有一个是OH或O-L-X，R6、R7和R8中至少有一个是OH或O-L-X。R4和R5，它们可以相同也可以不同，各自独立地是H；或者是一个取代或未取代的、饱和或不饱和的、环状基团；一个取代或未取代的、饱和或不饱和的杂环基团；或者是一个取代或未取代的、饱和或不饱和的、直链或支链烷基基团。还描述了包含本发明化合物的染料结合物。
• [EN] TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE<br/>[FR] DÉRIVÉS DE TÉTRAHYDROQUINOLINE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011054841A1

  公开（公告）日：2011-05-12

  Tetrahydroquinoline compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

  Formula (I)的四氢喹啉化合物及其盐，含有这种化合物的药物组合物以及它们在治疗中的用途。